The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: To determine whether cisplatin plus paclitaxel (C+P) improved response rate, progression-free survival (PFS), or survival compared with cisplatin alone in patients with stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix. Patients and Methods: Eligible patients with measurable disease, performance status (PS) 0 to 2, and adequate hematologic, hepatic, and renal function received either cisplatin 50 mg/m 2 or C+P (cisplatin 50 mg/m 2 plus paclitaxel 135 mg/m 2) every 3 weeks for six cycles. Tumor measurements and quality-of-life (QOL) assessments were obtained before each treatment cycle. Results: Of 280 patients entered, 6% were ineligible. Among 264 eligible patients, 134 received cisplatin and 130 received C+P. Groups were well matched with respect to age, ethnicity, PS, tumor grade, disease site, and number of cycles received. The majority of all patients had prior radiation therapy (cisplatin, 92%; C+P, 91%). Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002). The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001). There was no difference in median survival (8.8 months v 9.7 months). Grade 3 to 4 anemia and neutropenia were more common in the combination arm. There was no significant difference in QOL scores, although a disproportionate number of patients (cisplatin, n= 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death. Conclusion: C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citationApplication of random-effects pattern-mixture models for missing data in longitudinal studies.
Hedeker, D., & Gibbons, R. D. (1997) · Psychological Methods · doi:10.1037/1082-989x.2.1.64 · Cited by 907
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Self-citationCasagrande, J. T., Pike, M. C., & Smith, P. G. (1978) · Biometrics · doi:10.2307/2530613 · Cited by 431
Bonomi, P., Blessing, J. A., Stehman, F. B., DiSaia, P. J., Walton, L., & Major, F. J. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.8.1079 · Cited by 402
Self-citationRubinstein, L. V., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 267
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
McGuire, W. P., Blessing, J. A., Moore, D. H., Lentz, S. S., & Photopulos, G. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.792 · Cited by 217
Self-citationRose, P. G., Blessing, J. A., Gershenson, D. M., & McGehee, R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2676 · Cited by 206
Self-citationPAPADIMITRIOU, C. A., Sarris, K., Moulopoulos, L. A., Fountzilas, G., Anagnostopoulos, A., Voulgaris, Z., Gika, D., Giannakoulis, N., Diakomanolis, E., & Dimopoulos, M. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.761 · Cited by 101
Pignata, S., Silvestro, G., Ferrari, E., Selvaggi, L. E., Perrone, F., Maffeo, A., Frezza, P., Vagno, G. D., Casella, G., Ricchi, P., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.756 · Cited by 68
Cited by
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12611 · Cited by 1,134
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., Tewari, K. S., Salman, P., Hoyos Usta, E., Yañez, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112435 · Cited by 1,067
Metadata
- Authors
- Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., & Rocereto, T. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-01
- Volume
- 22
- Issue
- 15
- Pages
- 3113-3119
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2126768246
- Cited by
- 635
- References
- 10
- FWCI
- 28.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.